The market authorization came with a number of caveats and special requirements that 23andMe must follow when selling its PGx tests to consumers.
In development for several years, PORTIN is now being deployed as a single point of reference for all genotype and phenotype data at Bayer's research sites.
New work has looked at how common HLA peptide splicing is, which has significance for immunotherapy and infectious disease research.
Researchers identified 133 neuronal and non-neuronal cell types using single-cell RNA-seq data for tens of thousands of cells from the mouse neocortex.
The fully automated system has 12 independent thermal cyclers and runs the firm's diagnostic kits, but it can also operate as an open instrument.
In Genome Biology this week: comparative genomic study of endoderm differentiation, a single-cell sequencing method for small and messenger RNAs, and more.
An investigation found no evidence of bullying or gender discrimination, but did find management flaws at the Wellcome Trust Sanger Institute, the Guardian reports.
Dovetail offers genome assembly services for plant, animal, and microbial genomes based on its proprietary proximity ligation and sequencing protocol.
An analysis of matched tumor-normal samples from dozens of colorectal cancer patients pointed to microbiome differences related to mutations and other tumor features.
The telegenomics firm's 40 genetics experts will evaluate and make care decision for patients, and facilitate peer-to-peer consultations for providers.
At AMP, the companies announced a partnership to add Paragon Genomics' NGS target enrichment technologies to the flagship Sophia AI platform worldwide.
The assay can identify KRAS, NRAS, PIK3CA, BRAF, and EGFR gene mutations, as well as 19 gene rearrangements of the ALK, ROS1, RET, NTRK1, and MET genes from FFPE.
OpGen's research-use-only Acuitas AMR Gene Panel u5.47 is designed to detect multidrug-resistant bacterial pathogens in urine or bacterial isolates.
Early results from preemptive genomic testing are raising questions about the prevalence and penetrance of pathogenic variants, and who is pursuing such testing.
Agilent Technologies has launched Agilent OnePGT, a genome-wide, next-generation sequencing solution for preimplantation genetic testing. OnePGT allows parallel detection of multiple monogenic disorders, translocations, and aneuploidies from a single biopsy, going from biopsy to a single comprehensive report in a matter of days, Agilent said. The test is run on the company's Alissa platform, allowing for automatic calling of genetic abnormalities with built-in quality control metrics and an audit trail. This solution provides fertility specialists more comprehensive PGT data in order to help them identify the most viable embryos for transfer.
Uromonitor has launched its genetic test for detecting the recurrence of bladder cancer. Also called Uromonitor, the urine-based test detects trace amounts of FGFR3 and Tert promoter mutations, which are associated with early stages of bladder cancer. Portugal's Institute of Molecular Pathology and Immunology of the University of Porto, and the Institute for Research and Innovation in Health developed the test, which is CE marked.
HTG Molecular Diagnostics has appointed Maureen Cronin as its CSO and senior vice president, effective Nov. 16. Cronin served as executive director of strategic information management for Celgene from 2012 to 2017. Before that, she was senior vice president of research and product development for Foundation Medicine. She also served as VP of translational research and senior director of technology development at Genomic Health.
Laura Clague has been appointed to the board of directors of Fluidigm. She is the CFO of Retrophin. Previously, she was the CFO of the San Diego and Ohio operations of Amylin Pharmaceuticals, following the company's acquisition by Bristol-Myers Squibb. Prior to that, she was vice president, corporate controller, and principal accounting officer at Amylin, as well as CFO of Amylin's collaboration with Eli Lilly and Company. Clague holds a BS in business administration from Menlo College.
DefiniGen said it plans to use the Broad's technology to create disease models to support the development of therapeutics for metabolic diseases.
Two recent publications suggest that DeepVariant's machine learning is far superior to traditional methods of variant calling, especially with hardware accelerators.